Innovent Biologics (01801) Announces Monthly Return on Movements in Securities for January 2026

Bulletin Express

Feb 05

Innovent Biologics (01801) released its monthly return on movements in securities for the period ended 31 January 2026. The authorized share capital remains at 5,000,000,000 ordinary shares with a par value of USD 0.00001 per share, totaling USD 50,000 in authorized capital.

The number of issued shares (excluding treasury shares) rose from 1,734,623,465 to 1,735,186,039, reflecting an increase of 562,574 shares during the month. The company confirmed that it meets the prescribed public float requirement of 25%.

Changes in share options under different incentive plans include the issuance of 53,000 new shares from the Pre-IPO Share Incentive Plan and 509,574 new shares from the Post-IPO share option scheme, with 14,600 shares from the 2024 Share Scheme having lapsed. Total funds raised from exercised options amounted to HKD 19,975,088.9. No new shares were issued under any other arrangement this month, and no treasury shares were involved in any transactions.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1175959974"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1175959974\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1175959974?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-05 18:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1175959974","market":"hk","top_or_hot":-1,"title":"Innovent Biologics (01801) Announces Monthly Return on Movements in Securities for January 2026","media":"Bulletin Express","content":"<p>Innovent Biologics (01801) released its monthly return on movements in securities for the period ended 31 January 2026. The authorized share capital remains at 5,000,000,000 ordinary shares with a par value of USD 0.00001 per share, totaling USD 50,000 in authorized capital.</p>\n<p>The number of issued shares (excluding treasury shares) rose from 1,734,623,465 to 1,735,186,039, reflecting an increase of 562,574 shares during the month. The company confirmed that it meets the prescribed public float requirement of 25%.</p>\n<p>Changes in share options under different incentive plans include the issuance of 53,000 new shares from the Pre-IPO Share Incentive Plan and 509,574 new shares from the Post-IPO share option scheme, with 14,600 shares from the 2024 Share Scheme having lapsed. Total funds raised from exercised options amounted to HKD 19,975,088.9. No new shares were issued under any other arrangement this month, and no treasury shares were involved in any transactions.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innovent Biologics (01801) Announces Monthly Return on Movements in Securities for January 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnovent Biologics (01801) Announces Monthly Return on Movements in Securities for January 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-05 18:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Innovent Biologics (01801) released its monthly return on movements in securities for the period ended 31 January 2026. The authorized share capital remains at 5,000,000,000 ordinary shares with a par value of USD 0.00001 per share, totaling USD 50,000 in authorized capital.</p>\n<p>The number of issued shares (excluding treasury shares) rose from 1,734,623,465 to 1,735,186,039, reflecting an increase of 562,574 shares during the month. The company confirmed that it meets the prescribed public float requirement of 25%.</p>\n<p>Changes in share options under different incentive plans include the issuance of 53,000 new shares from the Pre-IPO Share Incentive Plan and 509,574 new shares from the Post-IPO share option scheme, with 14,600 shares from the 2024 Share Scheme having lapsed. Total funds raised from exercised options amounted to HKD 19,975,088.9. No new shares were issued under any other arrangement this month, and no treasury shares were involved in any transactions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01801","symbol_name":"信达生物","start_time":0,"source_url":"","article_id":"1175959974","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1175959974","pubTimestamp":1770287137,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Innovent Biologics (01801) released its monthly return on movements in securities for the period ended 31 January 2026. The authorized share capital remains at 5,000,000,000 ordinary shares with a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01801":"信达生物"},"translate_title":"信达生物(01801)公布2026年1月证券变动月报表","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1},"content_text":"Innovent Biologics (01801) released its monthly return on movements in securities for the period ended 31 January 2026. The authorized share capital remains at 5,000,000,000 ordinary shares with a par value of USD 0.00001 per share, totaling USD 50,000 in authorized capital.\nThe number of issued shares (excluding treasury shares) rose from 1,734,623,465 to 1,735,186,039, reflecting an increase of 562,574 shares during the month. The company confirmed that it meets the prescribed public float requirement of 25%.\nChanges in share options under different incentive plans include the issuance of 53,000 new shares from the Pre-IPO Share Incentive Plan and 509,574 new shares from the Post-IPO share option scheme, with 14,600 shares from the 2024 Share Scheme having lapsed. Total funds raised from exercised options amounted to HKD 19,975,088.9. No new shares were issued under any other arrangement this month, and no treasury shares were involved in any transactions.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}